Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Inhibrx
Biotech
Sanofi inks $1.7B Inhibrx buyout, snagging rare disease drug
Sanofi is set to buy Inhibrx for below the market price but then spin out all but one of its candidates to create a new publicly traded biotech.
Nick Paul Taylor
Jan 23, 2024 5:26am
Inhibrx pulls off $119M IPO on its 2nd go-around
Aug 20, 2020 10:21am
Hoping to win where Novartis failed, Inhibrx files for $75M IPO
Jun 4, 2019 9:26am
Five Prime cuts loose from InhibRx I-O deal
Aug 29, 2017 7:59am
